Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a private placement of up to 535,000 units priced at C$1.87 per unit, targeting gross proceeds of up to C$1,000,000. Each unit consists of one common share and one warrant exercisable at C$2.50 for three years, with an acceleration clause triggered if the share price sustains above C$4.80. The offering is expected to close on or around September 17, 2026, with proceeds earmarked for working capital and general corporate purposes.

Key Points

  • Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF)
  • Private placement of up to 535,000 units at C$1.87 per unit for gross proceeds of up to C$1,000,000
  • Warrants exercisable at C$2.50 for three years; acceleration clause applies if volume-weighted average price reaches C$4.80 for 30 consecutive trading days
  • Investors may watch for closing confirmation on or around September 17, 2026 and any subsequent warrant activity

Innocan Pharma's Unit Structure and Warrant Acceleration Terms

Each unit issued under the offering comprises one common share and one common share purchase warrant. Warrant holders may purchase one additional common share at C$2.50 per share for a period of three years from the date of issuance. The announcement includes an acceleration provision: should the daily volume-weighted average trading price of Innocan's common shares on the Canadian Securities Exchange equal or exceed C$4.80 for 30 consecutive trading days, the company may accelerate the warrant expiry to 30 days following written notice or a press release to subscribers.

Use of Proceeds and Finder's Fee Arrangements

Innocan states it intends to apply the net proceeds from the offering toward working capital and general corporate purposes. The company also disclosed that it intends to pay arm's-length finders a fee of 10% in cash and 8% in finder's warrants on amounts raised through those parties. Securities issued under the offering will be subject to a statutory hold period of four months and one day from the date of issuance, consistent with applicable Canadian securities laws and Canadian Securities Exchange policies.

Innocan Pharma's Pharmaceuticals and Wellness Business Background

Innocan describes itself as an innovator operating across the pharmaceuticals and wellness sectors. In the wellness segment, the company develops and markets self-care and beauty products intended to promote a healthier lifestyle. This segment is carried on through BI Sky Global Ltd., a 60%-owned subsidiary focused on advanced targeted online sales. The announcement does not provide updated revenue figures, product pipeline timelines, or operational milestones in connection with this offering.